Lupin gains on launching combination drugs for heart failure patients

Lupin gains on launching combination drugs for heart failure patients

by 5paisa Research Team Last Updated: Jan 19, 2023 - 09:30 am 3.1k Views

Today, the stock opened at Rs 753.00 and has touched a high and low of Rs 769.70 and Rs 753.00, respectively.

On Wednesday, shares of Lupin closed at Rs 766.90, up by 13.85 points or 1.84% from its previous closing of Rs 753.05 on the BSE.

Lupin has launched combination drugs Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in India. This drug combination is indicated for patients with Heart Failure (HF) conditions. Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg. Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure.

Commenting on the launch, Rajeev Sibal, President – India Region Formulations, Lupin said, “Heart failure is a difficult condition with severe unmet needs, necessitating the development of treatment agents to improve patient outcomes. As a leader in the cardiac therapy area, Lupin is committed to offering patients with treatment options that limit the need for hospitalization and reduce the risk of death. The launch of Valentas and Arnipin aligns with this commitment and offers patients an important treatment option and fulfils an unmet need while reducing the cost of therapy.” 

Lupin is an innovation-led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

The BSE group 'A' stock of face value of Rs 2 has a 52-week high and low of Rs 969.00 and Rs 583.05. Last one week high and low of the scrip stood at Rs 769.70 and Rs 745.15, respectively. The current market cap of the company is Rs 34,875.59 crore.

The promoters holding in the company stood at 47.10%, while Institutions and Non-Institutions held 43.36% and 9.53% respectively.

How do you rate this article?


Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.


Investment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.

Open Free Demat Account

Resend OTP
Please Enter OTP
Account belongs to

By proceeding, you agree to the T&C.

Latest News
Sahana Systems IPO GMP (Grey Market Premium)

Sahana Systems IPO worth ₹32.74 crore comprises entirely of a fresh issue of shares by the company. The price band has been fixed in the range of ₹132 to ₹135.

  • Jun 07, 2023
Spectrum Talent Management IPO GMP (Grey Market Premium)

The ₹105.14 crore IPO of Spectrum Talent Management IPO comprises entirely of a combination of a fresh issue of shares and an offer for sale (OFS) by promoters and early shareholders.

  • Jun 07, 2023
IKIO Lighting IPO GMP (Grey Market Premium)

IKIO Lighting IPO worth ₹607 crore comprises of an offer for sale and also of a fresh issue of shares. The offer for sale (OFS) component is by the promoters and early shareholders of the company.

  • Jun 07, 2023

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number